Provided by Tiger Fintech (Singapore) Pte. Ltd.

Organon & Co

15.92
+0.48003.11%
Volume:1.74M
Turnover:27.63M
Market Cap:4.11B
PE:4.78
High:16.07
Open:15.37
Low:15.35
Close:15.44
Loading ...

BRIEF-FDA Approves Dermavant Science's Vtama For Topical Treatment Of Atopic Dermatitis In Adult & Pediatric Patients 2 Years & Older

Reuters
·
14 Dec 2024

FDA: Approves Dermavant Science's Vtama for Topical Treatment of Atopic Dermatitis in Adult & Pediatric Patients 2 Years & Older - Website

THOMSON REUTERS
·
14 Dec 2024

Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price

Simply Wall St.
·
13 Dec 2024

Merck-marketed asthma drug linked to psychiatric issues: report

seekingalpha
·
22 Nov 2024

Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem

Simply Wall St.
·
08 Nov 2024

Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Simply Wall St.
·
06 Nov 2024

Organon Says FDA Extended Review of VTAMA's Supplemental New Drug Application

MT Newswires Live
·
05 Nov 2024

Stock Track | Organon Plunges as FDA Delays Review of Atopic Dermatitis Drug VTAMA

Stock Track
·
05 Nov 2024

Organon: FDA Extends Vtama Atopic-Dermatitis Review to March

Dow Jones
·
05 Nov 2024

Organon updates outlook as FDA delays VTAMA label expansion

seekingalpha
·
05 Nov 2024

Stock Track | Organon Surges as FDA Extends Review for Potential AD Treatment VTAMA

Stock Track
·
05 Nov 2024

BRIEF-Update On FDA Review Of VTAMA Cream 1% For Atopic Dermatitis In Adults And Children Aged 2 And Older

Reuters
·
05 Nov 2024

Organon & Co - FDA Raises No Safety or Efficacy Concerns for Vtama

THOMSON REUTERS
·
05 Nov 2024

Organon & Co - New Target Date for Vtama Review Is March 12, 2025

THOMSON REUTERS
·
05 Nov 2024

Update on FDA Review of Vtama® (Tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

THOMSON REUTERS
·
05 Nov 2024

Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Simply Wall St.
·
01 Nov 2024